Lidocaina Cloridrato Monico

Lidocaine, the active ingredient in Lidocaina Cloridrato Monico, is a local anesthetic presented as a sterile solution for infiltration use. It provides local anesthesia for minor surgical procedures and infiltration anesthesia.

GNH USA supplies Lidocaina Cloridrato Monico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine is a local anesthetic used to block nerve conduction in minor surgical and procedural settings. - Minor surgical procedures: provides local anesthesia to facilitate pain‑free incision and manipulation. - Dental procedures: enables infiltration anesthesia for tooth extractions and restorative work. - Dermatologic procedures: allows local anesthesia for skin biopsies and minor excisions.

Lidocaine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Transient burning or stinging at the injection site. - Mild erythema or redness around the administration area. - Tingling or numbness that persists briefly after the procedure. - Localized swelling or edema.

Serious or Rare Side Effects: - Systemic toxicity presenting as central nervous system depression, seizures, or coma. - Cardiac arrhythmias, including ventricular tachycardia or heart block. - Severe allergic reactions such as anaphylaxis. - Methemoglobinemia, a rare blood disorder causing reduced oxygen delivery.

When using Lidocaina Cloridrato Monico, clinicians should observe several safety measures. - Assess patient allergy: verify no known lidocaine hypersensitivity before administration. - Use lowest effective dose: limit total dose per procedure according to clinical guidelines. - Monitor cardiac status: observe for arrhythmias in patients with pre‑existing heart disease. - Avoid intravascular injection: aspirate before injection to prevent systemic exposure. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lidocaine can interact with other medications, requiring careful assessment.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine plasma concentrations and toxicity risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise systemic exposure to lidocaine.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance central nervous system effects of lidocaine. - Concurrent use of other local anesthetics: additive toxicity potential. - Loop diuretics (e.g., furosemide): may potentiate cardiac effects when combined with lidocaine.